Patents by Inventor Daniel Magilavy

Daniel Magilavy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment for vitiligo
    Patent number: 9730930
    Abstract: Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: August 15, 2017
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Daniel Magilavy
  • TREATMENT FOR VITILIGO
    Publication number: 20150246039
    Abstract: Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Daniel Magilavy
  • Treatment for vitiligo
    Patent number: 9034881
    Abstract: Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: May 19, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventor: Daniel Magilavy
  • TREATMENT FOR VITILIGO
    Publication number: 20140073659
    Abstract: Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 13, 2014
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Daniel Magilavy
  • TREATMENT FOR DISCOID LUPUS
    Publication number: 20130274277
    Abstract: Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.
    Type: Application
    Filed: May 30, 2013
    Publication date: October 17, 2013
    Inventors: Daniel Magilavy, Polly Pine
  • Treatment for discoid lupus
    Patent number: 8497279
    Abstract: Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: July 30, 2013
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Daniel Magilavy, Polly Pine
  • TREATMENT FOR DISCOID LUPUS
    Publication number: 20120232106
    Abstract: Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Inventors: Daniel Magilavy, Polly Pine
  • Methods of treating skin disorders
    Publication number: 20070172478
    Abstract: Methods of treating skin disorders are provided.
    Type: Application
    Filed: February 7, 2005
    Publication date: July 26, 2007
    Applicant: ASTELLAS US LLC
    Inventor: Daniel Magilavy
  • Method of modulating memory effector T-cells and compositions
    Publication number: 20060233796
    Abstract: This invention relates to methods of using inhibitors of the CD2/LFA-3 interaction in treating conditions characterized by the presence of activated T cells in mammals, including humans. Such conditions include inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis.
    Type: Application
    Filed: April 6, 2006
    Publication date: October 19, 2006
    Inventor: Daniel Magilavy
  • Method of modulating memory effector T-cells and compositions
    Publication number: 20020009446
    Abstract: This invention relates to methods of using inhibitors of the CD2/LFA-3 interaction in treating conditions characterized by the presence of activated T cells in mammals, including humans. Such conditions include inflammatory bowel diseases, psoriatic arthritis, rheumatoid arthritis, and multiple sclerosis.
    Type: Application
    Filed: February 27, 2001
    Publication date: January 24, 2002
    Inventor: Daniel Magilavy